Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch

Reuters

06-16

Intellia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch

CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema $(HAE)$ using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application $(BLA.AU)$ in 2026 to support a U.S. launch in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543867970"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543867970\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543867970?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543867970","market":"fut","top_or_hot":-1,"title":"Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> in 2026 to support a U.S. launch in 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NTLA\">Intellia Therapeutics Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-16 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> in 2026 to support a U.S. launch in 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NTLA\">Intellia Therapeutics Inc</a>. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4556","symbol_name":"基因編輯","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL8Fnvr1:1","article_id":"2543867970","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543867970","pubTimestamp":1750071692,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CAMBRIDGE, Mass. June 15, 2025  - Intellia Therapeutics, Inc. , a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema  using a single dose of lonvoguran ziclumeran . The results were presented at the European Academy of Allergy and Clinical Immunology  Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application  in 2026 to support a U.S. launch in 2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4556":"基因编辑","BK4588":"碎股","BK4585":"ETF&股票定投概念","NTLA":"Intellia Therapeutics Inc","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4139":"生物科技","BK4535":"淡马锡持仓","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD"},"translate_title":"Intellia Therapeutics宣布Lonvo-z有希望的3期试验结果，计划于2027年在美国上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":0.9},"content_text":"Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch\n    \n\n        CAMBRIDGE, Mass. June 15, 2025 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a clinical-stage gene editing company, has announced three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study in patients with hereditary angioedema $(HAE)$ using a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). The results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. The Phase 3 HAELO trial, a global, randomized, double-blind, placebo-controlled study, has completed screening ahead of schedule, with over half of the participants screened in the United States. Intellia plans to report the outcomes of the Phase 3 study in the first half of 2026 and aims to submit a biologics license application $(BLA.AU)$ in 2026 to support a U.S. launch in 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-141087), on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}